Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

A plasma microRNA biomarker of melanoma as a personalised assessment of treatment response.

van Laar RK, Lincoln MT, van Laar BJ.

Melanoma Res. 2019 Feb;29(1):19-22. doi: 10.1097/CMR.0000000000000492.

PMID:
30320629
2.

BreastPRS is a gene expression assay that stratifies intermediate-risk Oncotype DX patients into high- or low-risk for disease recurrence.

D'Alfonso TM, van Laar RK, Vahdat LT, Hussain W, Flinchum R, Brown N, John LS, Shin SJ.

Breast Cancer Res Treat. 2013 Jun;139(3):705-15. doi: 10.1007/s10549-013-2604-0. Epub 2013 Jun 18.

PMID:
23774991
3.
4.

Design and multiseries validation of a web-based gene expression assay for predicting breast cancer recurrence and patient survival.

Van Laar RK.

J Mol Diagn. 2011 May;13(3):297-304. doi: 10.1016/j.jmoldx.2010.12.003. Epub 2011 Mar 31.

5.

An online gene expression assay for determining adjuvant therapy eligibility in patients with stage 2 or 3 colon cancer.

Van Laar RK.

Br J Cancer. 2010 Dec 7;103(12):1852-7. doi: 10.1038/sj.bjc.6605970. Epub 2010 Nov 30.

6.

Implementation of a novel microarray-based diagnostic test for cancer of unknown primary.

van Laar RK, Ma XJ, de Jong D, Wehkamp D, Floore AN, Warmoes MO, Simon I, Wang W, Erlander M, van't Veer LJ, Glas AM.

Int J Cancer. 2009 Sep 15;125(6):1390-7. doi: 10.1002/ijc.24504.

7.

Gene expression profiling to identify the histogenetic origin of metastatic adenocarcinomas of unknown primary.

Horlings HM, van Laar RK, Kerst JM, Helgason HH, Wesseling J, van der Hoeven JJ, Warmoes MO, Floore A, Witteveen A, Lahti-Domenici J, Glas AM, Van't Veer LJ, de Jong D.

J Clin Oncol. 2008 Sep 20;26(27):4435-41. doi: 10.1200/JCO.2007.14.6969.

PMID:
18802156
8.

Comparison of gene expression profiles predicting progression in breast cancer patients treated with tamoxifen.

Kok M, Linn SC, Van Laar RK, Jansen MP, van den Berg TM, Delahaye LJ, Glas AM, Peterse JL, Hauptmann M, Foekens JA, Klijn JG, Wessels LF, Van't Veer LJ, Berns EM.

Breast Cancer Res Treat. 2009 Jan;113(2):275-83. doi: 10.1007/s10549-008-9939-y. Epub 2008 Mar 4.

PMID:
18311582
9.

Location of, immunogenicity of and relationships between neutralization epitopes on the attachment protein (G) of Hendra virus.

White JR, Boyd V, Crameri GS, Duch CJ, van Laar RK, Wang LF, Eaton BT.

J Gen Virol. 2005 Oct;86(Pt 10):2839-48.

PMID:
16186240
10.

An expression-based site of origin diagnostic method designed for clinical application to cancer of unknown origin.

Tothill RW, Kowalczyk A, Rischin D, Bousioutas A, Haviv I, van Laar RK, Waring PM, Zalcberg J, Ward R, Biankin AV, Sutherland RL, Henshall SM, Fong K, Pollack JR, Bowtell DD, Holloway AJ.

Cancer Res. 2005 May 15;65(10):4031-40. Erratum in: Cancer Res. 2005 Sep 1;65(17):8057.

11.

Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors.

Peart MJ, Smyth GK, van Laar RK, Bowtell DD, Richon VM, Marks PA, Holloway AJ, Johnstone RW.

Proc Natl Acad Sci U S A. 2005 Mar 8;102(10):3697-702. Epub 2005 Feb 28.

12.

Genomic analysis of a spontaneous model of breast cancer metastasis to bone reveals a role for the extracellular matrix.

Eckhardt BL, Parker BS, van Laar RK, Restall CM, Natoli AL, Tavaria MD, Stanley KL, Sloan EK, Moseley JM, Anderson RL.

Mol Cancer Res. 2005 Jan;3(1):1-13.

13.

Options available--from start to finish--for obtaining data from DNA microarrays II.

Holloway AJ, van Laar RK, Tothill RW, Bowtell DD.

Nat Genet. 2002 Dec;32 Suppl:481-9. Review.

PMID:
12454642

Supplemental Content

Loading ...
Support Center